The 50 biggest pharmaceutical companies in Romania last year
generated turnover worth 1.79bn euros, namely 1.5% in GDP,
according to ZF calculations based on data from Cegedim market
research firm. They saw sales go down by around 2% (in euros)
against 2008 results, but generated almost 94% of the entire market
together. The top position in the ranking is held by
Sanofi-Aventis, which came to be the leader after acquiring
Zentiva, with turnover worth above 190m euros, while the company
ranking 50th, Mundipharma, derives around 3m euros. The best
results were registered by US Amgen, with a 52% advance, while
Standa and Labormed coped with the steepest declines. Dan Vasile,
general manager of Biofarm, believes such increases were generated
by a series of conditions, which have not been specific to the
Romanian market so far. Overall, 21 pharmaceutical companies posted
growth, three saw their figures stagnate and the rest of 26
companies posted declines. The top 20 companies account for almost
80% in sales, compared with 70% a year ago, but the industry is
witnessing a strong concentration trend.

Subiecte #Cegedim:#pharmaceutical companies